Efficacy of different therapeutic plant extracts and nanoparticles against pathogenic strains of Streptococcus pneumoniae isolated from ophthalmic infections
Antibacterial effect of therapeutic plants against S. pneumonia
DOI:
https://doi.org/10.17720/ke5wd557Keywords:
Ophthalmic infections, Streptococcus pneumonia, Tryptic soy agar, Chocolate agar, Hemolysis, Antibiotic, Green synthesized silver nano-particles, Plant extractAbstract
Background: In recent years, eye infections are very common medical problem, which may be partly due to increasing in contact lens wearers. Objective: The objective of this study was to identify and characterize the microorganisms responsible for corneal infections. There is a significant public health concern regarding ophthalmic infections, particularly in environments that are contaminated. Methodology: Samples of eye swabs were collected from Fatima Memorial Hospital located in Shadman, Lahore. Samples were spread on Tryptic soy agar (TSA) and after that streaked on chocolate agar media for isolation of pure culture. After isolation of pure bacterial strains, pathogenicity of strains were checked by Blood agar test. Strains showed alpha hemolysis were choose and these strains were checked against different antibiotics, green synthesized silver Nano-particles of different plant extract and also against plant extract. Results: Four strains exhibited alpha hemolysis, indicating the presence of pathogenic strains of Streptococcus pneumoniae, which are implicated in ocular infections. Zone of inhibitions (ZOI) were observed against different antibiotics, green synthesized silver Nano-particles of different plant extract and also against plant extract by some isolated bacterial strains but others showed resistance. Conclusion: The development of an effective and accessible treatment could contribute to global public health improvement. Accessible treatments may lead to better health outcomes, particularly in regions where ophthalmic infections are prevalent but access to advanced medical interventions is limited.
Downloads
References
I. Baral B, Mamale K, Gairola S, Chauhan C, Dey A, Kaundal R K. Infectious diseases and its global epidemiology. In Nanostructured Drug Delivery Systems in Infectious Disease Treatment 2024; (pp. 1-24). Academic Press.
II. Almutleb E S, El-Hiti G A, Alshulayyil A N, Alghamdi A D, Almutairi M S, Baashen M A, Masmali A M. Assessment of lipid layer patterns in domestic dogs and rabbits: an observational study. Open Veterinary Journal 2024; 14(3) 879.
III. Ananthapadmanabasamy I, Shambhavi G K, Rao C S. Bacteriological Profile and Antimicrobial Susceptibility Pattern of Isolates from Ocular Infections among the Patients Attending Ophthalmology Department of a Tertiary Care Hospital. J Clin Micro Infec Vol 2021; 4(5) 1.
IV. Deepthi K, Jereesh A S. An ensemble approach for CircRNA-disease association prediction based on autoencoder and deep neural network. Gene 2020; 762 145040.
V. Matysiak A, Kabza M, Karolak J A, Jaworska M M, Rydzanicz M, Ploski R, Gajecka M. Characterization of ocular surface microbial profiles revealed discrepancies between conjunctival and corneal microbiota. Pathogens 2021; 10(4) 405.
VI. Gotmare N, Jain P, Arora R, Gupta I. Consequences of traditional eye medication use in developing countries: A perspective. Journal of Clinical Ophthalmology and Optometry Research 2021; 1(1) 1-4.
VII. Maiti S, Gandhi J, Joseph J. Microbiological spectrum and antibiotic susceptibility patterns of non-viral conjunctivitis over 16 years at a tertiary eye care center in Southern India. International Ophthalmology 2023; 43(10) 3717-3724.
VIII. Haidar A, Sharif J, Nadeem A, Perveen A, Muazzam A, Naveed A, Samad A. Bacterial conjunctivitis: clinical features, types and complications; a systematic review. Advanced Research in Medical and Health Sciences 2024; 2(1) 1-9.
IX. Bhattacharya M, Horswill A R. The role of human extracellular matrix proteins in defining Staphylococcus aureus biofilm infections. FEMS Microbiology Reviews 2024; 48(1) fuae002.
X. Liu S H, Hawkins B S, Ng S M, Ren M, Leslie L, Han G, Kuo I C.Topical pharmacologic interventions versus placebo for epidemic keratoconjunctivitis. Cochrane Database of Systematic Reviews 2022; (3).
XI. Zikic A, Schünemann H, Wi T, Lincetto O, Broutet N, Santesso N. Treatment of neonatal chlamydial conjunctivitis: a systematic review and meta-analysis. Journal of the Pediatric Infectious Diseases Society 2018; 7(3) e107-e115.
XII. Muto T, Imaizumi S, Kamoi K. Viral conjunctivitis. Viruses 2023; 15(3) 676.
XIII. Petrillo F, Tortori A, Vallino V, Galdiero M, Fea A M, De Sanctis U, Reibaldi M. Understanding Acanthamoeba Keratitis: An in-depth review of a sight-threatening eye infection. Microorganisms 2024; 12(4) 758.
XIV. Tahmasebi E, Keshvad A, Alam M, Abbasi K, Rahimi S, Nouri F, Fernandes G V O. Current infections of the orofacial region: treatment, diagnosis, and epidemiology. Life 2023; 13(2) 269.
XV. Soleimani M, Tabatabaei S A, Masoumi A, Mirshahi R, Ghahvechian H, Tayebi F, Mohammadi S S. Infectious keratitis: trends in microbiological and antibiotic sensitivity patterns. Eye 2021; 35(11) 3110-3115.
XVI. Modem P, Rani K S E, Gumpali M, Mallampeta A, Yerekar S. An Overview of Pink Eye Inflammation and its Effect on Public Health. International Journal of Research in Engineering, Science and Management 2024; 7(5) 45-50.
XVII. Antony F, Kinha D, Nowińska A, Rouse B T, Suryawanshi A. The immunobiology of corneal HSV-1 infection and herpetic stromal keratitis. Clinical Microbiology Reviews 2024; e00006-24.
XVIII. Musa M, Enaholo E, Aluyi-Osa G, Atuanya G N, Spadea L, Salati C, Zeppieri M. Herpes simplex keratitis: A brief clinical overview. World Journal of Virology 2024; 13(1).
XIX. Ramos M F, Attar M, Seals J R, Luhrs K A. Safety evaluation of ocular drugs. A comprehensive guide to toxicology in nonclinical drug development 2024; 879-944.
XX. Ahmad S, Ahmad S, Qais F A, Khan M S, Ahmad I. Emergence and Spread of Multidrug Resistance in Ocular Bacterial Pathogens: A Current Update. Antibacterial Drug Discovery to Combat MDR: Natural Compounds, Nanotechnology and Novel Synthetic Sources 2019; 71-93.
XXI. Bihaniya H, Rudraprasad D, Joseph J. Pathobiology of Fungal Endophthalmitis: A Major Review. ACS Infectious Diseases 2024.
XXII. Ghazaei C. Targeted Therapy for Intracellular Bacterial Pathogens. International Journal of Basic Science in Medicine 2024; 9(1) 36-44.
XXIII. Moreddu R, Vigolo D, Yetisen A K. Contact lens technology: from fundamentals to applications. Advanced healthcare materials 2019; 8(15) 1900368.
XXIV. Fraser S. Climate Change and Eye Disease: Eye Health and Blindness in a Hostile Environment 2024; Taylor & Francis.
XXV. Cameron S. Chronic Wounds in the Community: A Smart Device Approach to Detecting the Early Onset of Infection 2023; (Doctoral dissertation, Ulster University).
XXVI. Maier P, Betancor P K, Reinhard T. Contact lens–associated keratitis—an often underestimated risk. Deutsches Ärzteblatt International 2022; 119(40) 669.
XXVII. Gupta A, Bansal R, Sharma A, Kapil A. Red Eyes—Conjunctivitis, Corneal Ulcers, Dry Eye Disease, and Acute Uveitis. In Ophthalmic Signs in Practice of Medicine 2024; (pp. 493-542). Singapore: Springer Nature Singapore.
XXVIII. Berkley J A. Bacterial infections and nutrition: a primer. Nutrition and Infectious Diseases: Shifting the Clinical Paradigm 2021; 113-131.
XXIX. Chinemerem Nwobodo D, Ugwu M C, Oliseloke Anie C, Al‐Ouqaili M T, Chinedu Ikem J, Victor Chigozie U, Saki M. Antibiotic resistance: The challenges and some emerging strategies for tackling a global menace. Journal of clinical laboratory analysis 2022; 36(9) e24655.
XXX. Haque S, Ahmed A, Islam N, Haque F K M. High Prevalence of Multidrug-Resistant Bacteria in the Trachea of Intensive Care Units Admitted Patients: Evidence from a Bangladeshi Hospital. Antibiotics 2024; 13(1) 62.
XXXI. Ung L, Chodosh J. Urgent unmet needs in the care of bacterial keratitis: An evidence-based synthesis. The ocular surface 2023; 28 378-400.
XXXII. Romandini A, Pani A, Schenardi P A, Pattarino G A C, De Giacomo C, Scaglione F. Antibiotic resistance in pediatric infections: global emerging threats, predicting the near future. Antibiotics, 2021; 10(4) 393.
XXXIII. Marasini S, Craig J P, Dean S J, Leanse L G. Managing Corneal Infections: Out with the old, in with the new? Antibiotics 2023; 12(8), 1334.
XXXIV. Abdallah E M, Alhatlani B Y, de Paula Menezes R, Martins C H G. Back to Nature: Medicinal plants as promising sources for antibacterial drugs in the post-antibiotic era. Plants 2023; 12(17) 3077.
XXXV. Aladejana E B, Adelabu O A, Aladejana A E, Ndlovu S I. Antimicrobial Properties of Alternative Medicines Used in the Management of Infections in Diabetic Patients: A Comprehensive Review. Pharmacological Research-Modern Chinese Medicine 2024; 100432.
XXXVI. Clare G, Kempen J H, Pavésio C. Infectious eye disease in the 21st century—an overview. Eye 2024; 1-14.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Author
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
